Cutting-edge research supported by Mats Paulsson Foundations
In connection with the official announcement of the 2025 donation recipients by the Mats Paulsson Foundation for Research, Innovation and Societal Development, Medicon Village invites you to join us in exploring the achievements of a previous grant recipient from Mats Paulsson Foundations.
Sustainable Gene Therapy Innovation: Platforms, Tools, and Talent
Discover how Lund Stem Cell Center drives advances in stem cell science – transforming research into treatments for cancer, blood disorders, and neurological conditions, and helping to shape a healthier future for all.
If we want more gene therapies to reach patients, we need available tools and skilled people. In Skåne, large efforts are underway to build the talent and create the conditions for faster, safer, and more equitable patient access to these revolutionary treatments.
Three Takeaways
- More gene therapy to patients with open tools – freely available delivery systems for genetic material remove barriers and speed up innovation.
- Lund University is building future talent through the Lund Stem Cell Centre – offering new education programs focused on therapies using living cells and genes.
- Collaboration is the catalyst – when education, infrastructure, and policy align, gene therapies will reach patients faster.
Agenda
Moderator: Sarah Lidé, Deputy CEO, Medicon Village Innovation.
11:30-12:00 Lunch mingel
12:00-12:05 Welcome by moderator
Sarah Lidé, Deputy CEO, Medicon Village Innovation
12:05-12:30 Sustainable Gene Therapy Innovation: Platforms, Tools, and Talent
Johan Flygare, Senior lecturer, Division of Molecular Medicine and Gene Therapy; Research team manager, Stem Cells to Red Blood Cells; Principal investigator, StemTherapy: National Initiative on Stem Cells for Regenerative Therapy; Principal investigator, LUCC: Lund University Cancer Centre; Deputy head of department, Department of Laboratory Medicine, Lund University.
12:30-12:45 Q&A, Looking to the future.
The event is co-funded by the EU as part of the ATMP Path2Patient project.